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Objective: Endografts represent a relatively new treatment modality for occlusive disease of the superﬁcial femoral artery,
with promising results. However, endografts may occlude collateral arteries, which may affect outcome in case of failure.
The purpose of this study was to analyze the clinical outcome of failed endografts in patients with superﬁcial femoral
artery occlusive disease.
Methods: All patients treated with one or more polytetraﬂuorethylene-covered stents between November 2001 and
December 2011 were prospectively included in a database. Patients with a failure of the endograft were retrospectively
analyzed. Clinical and hemodynamic parameters were assessed before the initial procedure and at the time of failure.
Outcome of secondary procedures was analyzed.
Results: Among the 341 patients who were treated during the study period, 49 (14.4%) failed during follow-up. Mean
(standard deviation) Rutherford category at failure did not differ from the category as scored before the initial procedure
(3.1 [1.3] vs 3.3 [0.6]; P[ .33). Forty-three percent of patients (n[ 21) presented with the same Rutherford category
as before the initial procedure, 37% (n[ 18) with an improved category, and 20% (n[ 10) with a deteriorated category.
The ankle-brachial index was signiﬁcantly lower at the time of failure (0.66 [0.19] vs 0.45 [0.19[; P <.002). Seventy-six
percent of patients with a failure needed secondary surgery, of which 25% were below knee. The 1-year primary, primary-
assisted, and secondary patency rates of secondary bypasses were 55.1%, 62.3%, and 77.7%, respectively. The amputation
rate was 4.1% (n [ 2).
Conclusions: Failure of endografts is not associated with a deterioration in clinical state and is related to a low amputation
rate. The hypothesis that covered stents do not affect options for secondary reconstructions could not be conﬁrmed, as
25% of patients with a failure underwent a below-knee bypass. Secondary surgical bypasses are correlated with poor
patency. The amputation rate after failure is low. (J Vasc Surg 2013;57:415-20.)Nitinol stents have improved the outcome of endovas-
cular treatment of occlusive disease of the superﬁcial
femoral artery (SFA). Randomized trials have shown their
superiority in lesions from 6.5 to 9.5 cm long,1,2 whereas
no differences have been reported for shorter lesions
compared to angioplasty only.3 In more extensive lesions,
bare metal stents are likely to perform worse due to the
occurrence of in-stent restenosis. Therefore, surgical recon-
struction is still the gold standard for lesions longer than 15
cm.4 However, bypass surgery is associated with complica-
tions and prolonged hospital stay.
The use of covered stents may improve the results of
endovascular treatment of more extensive disease in the
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://dx.doi.org/10.1016/j.jvs.2012.08.068likely due to large variances in both lesion and patient char-
acteristics. In a multicenter randomized trial, McQuade
et al5 reported that, using endografts, similar patency rates
were achieved compared to above-knee (AK) femoropopli-
teal bypasses after 4 years of follow-up, without differences
in complication rates. With the development of heparin-
bonding technology, the results of endografts may improve
further. In a recent study, 1-year primary patency of 75%,
primary-assisted patency of 81.7%, and secondary patency
of 89% were reported from a series of mostly TransAtlantic
InterSociety Consensus (TASC-II) D lesions.6
A possible shortcoming of covered stents might be the
coverage of collateral arteries. Such coverage is believed to
reduce the limb salvage rate or possibly change the level of
amputation after graft failure. However, in the above
mentioned randomized trial,5 failure of endografts did
not increase the amputation rate. The aim of the present
study was twofold: ﬁrst, to study the clinical state of
patients who presented with a failure of covered stents
used for SFA occlusive disease that possibly had covered
collateral arteries, and, second, to assess the outcome of
eventual secondary reconstructions in case of failure.
METHODS
Information on all patients treated with a polytetraﬂuor-
ethylene-covered endograft between November 2001 and
December 2011 in the Rijnstate Hospital Arnhem, the Isala
Clinics Zwolle, and the Antonius Hospital Sneek,415
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The indication for endovascular treatment was based on
anatomic suitability and the preference of both the patient
and the surgeon. All patients had an indication for surgery,
and treatment with an endograft was offered as a minimally
invasive alternative. Routine follow-up consisted of clinical
assessment, ankle-brachial index (ABI) measurements, and
ultrasound studies at 1, 3, 6, and 12months and yearly there-
after. Complications and additional treatments were regis-
tered in the hospital ﬁles.
All patients who presented with a failed endograft,
either clinically or during routine surveillance, were
included in the study and retrospectively analyzed. Demo-
graphics, clinical status, and medical history were noted.
Procedural aspects of the initial procedure and follow-up
data were retrieved, as was follow-up of a secondary proce-
dure if applicable. Cardiovascular risk factors were scored
according to the Society for Vascular Surgery medical
comorbidity grading system. Clinical symptoms at the
time of the initial procedure and symptoms at the time of
failure were categorized according to the Rutherford clas-
siﬁcation. ABI measurements at the time of failure were
compared with ABI measurements before insertion of the
endografts. Lesions were reviewed at the time of the initial
procedure and at the time of failure, and scored according
to the TASC-II criteria by two authors (M.L., B.G).4 The
number and patency of the runoff vessels were scored at
both time points. Patency of runoff vessels was classiﬁed
as open, open with stenosis (peak systolic velocity ratio
>2.5), or occlusion. The outcome of all secondary proce-
dures was assessed, as was the limb salvage rate.
Treatment protocol. The treatment protocol has
been previously described.6 Brieﬂy, the common femoral
artery was approached either percutaneously or surgically.
When there was a concomitant lesion in the common or
profunda femoral artery, an endarterectomy was per-
formed. Heparin and antibiotic prophylaxis were adminis-
tered. The diseased segment was passed, either
endoluminally or subintimally, using a 0.035-inch Terumo
Glidewire (Radiofocus Guidewire M; Terumo Medical
Corp, Elkton, Md) and a catheter, and a subsequent
reentry was created distally. The segment was predilated,
and endografts (Viabahn Endoprosthesis; W. L. Gore &
Associates, Flagstaff, Ariz) were positioned from distal to
proximal with minimal or no oversizing. Sizing was per-
formed using a computed tomographic or magnetic reso-
nance scan. The entire diseased segment was covered with
endografts, which were postdilated with an angioplasty
balloon of the same size as the endograft. Control angi-
ography of the endograft and outﬂow vessels was per-
formed routinely. Postprocedurally, patients received statin
treatment and dual antiplatelet inhibitors, unless oral
anticoagulation was indicated for other reasons.
Deﬁnitions. Failure of the endograft was deﬁned as
occlusion of the endograft, with or without clinical symp-
toms, not responding to ﬁbrinolytic or surgical therapy or
not eligible for therapy. An occlusion was deﬁned as the
absence of ﬂow in the treated segment of the SFA. Primarypatency was deﬁned as the absence of restenosis or occlu-
sion in the target vessel. Restenosis was deﬁned as a peak
systolic velocity ratio >2.5 as measured on ultrasound
scanning. Primary-assisted patency was deﬁned as patency
achieved by secondary endovascular interventions to treat
restenosis of the target vessel. Secondary patency was
deﬁned as patency after thrombolytic or surgical treatment
performed for bypass occlusion. Limb salvage was deﬁned
as the absence of an above-ankle amputation.
End points. The primary endpoints of the study were
comparison of the initial and postfailure Rutherford cate-
gories and the clinical outcome of failures, including
amputation rate, and patency rates of eventual secondary
interventions. Secondary end points were the differences
between initial and postfailure ABI, and the differences
between the quality of outﬂow vessels at the initial proce-
dure and postfailure.
Statistical analysis. Continuous variables are presented
as mean (standard deviation) or median with range;
nonparametric values as median (standard deviation) and
range; and categorical variables as count and percentage.
Univariate analyses were performed to identify a possible
inﬂuence of various confounding factors acting on the Ruth-
erford classiﬁcation at the time of failure. Kaplan-Meier
survival analysis was performed to assess primary patency
after secondary surgical intervention.P< .05was considered
statistically signiﬁcant. Data were analyzed using IBM SPSS
Statistics (version 19; IBM, Armonk, NY).
RESULTS
During the study period, a total of 341 patients were
treated with an endograft for occlusive SFA disease.
Median follow-up was 24 months (range, 0-72 months).
During follow-up, 49 patients presented with an occluded
endograft. The majority of these patients were male
(67.3%), and the mean age was 66 (9) years. The incidence
of cardiovascular risk factors is given in Table I.
Before the initial procedure, three patients (6.1%) had
already undergone balloon angioplasty of the SFA without
stent placement, and ﬁve (10.2%) had undergone angioplasty
of the iliac artery with (n¼ 3) or without (n¼ 2) bare metal
stent placement. Two patients were treated for an abdominal
aneurysm with an endograft, and one had undergone an
endarterectomy of the ipsilateral proximal SFA.
Initial procedure. Before the initial procedure, the
Rutherford classiﬁcation was category 3 in 38 patients
(77.6%), category 4 in nine patients (18.4%), category 5
in one patient (2%), and category 6 in one patient (2%).
Mean maximum walking distance for patients with
disabling claudication was 143 6 91 meters. Before treat-
ment, mean ABI at rest was 0.66 6 0.19 and after exer-
cise was 0.39 6 0.15. Two lesions (4.1%) were classiﬁed
as TASC-II A lesions, 14 (28.6%) as TASC-II B lesions,
14 (28.6%) as TASC-II C lesions, and 19 (38.7%) as
TASC-II D lesions. Mean lesion length of the SFA was
13.4 (10.0) cm, and ﬁve patients (10.2%) had a ﬂush
occlusion of the SFA. Other lesion characteristics are listed
in Table II.
Table I. Incidence of cardiovascular risk factors of
patients presenting with an occluded endograft
Cardiovascular risk factor
No. of
patients (%)
Hyperlipidemia
Normal cholesterol 11 (22.4%)
Mildly elevated, dietary 1 (2%)
Type II, III, IV, dietary 0 (0%)
Treated with drugs 36 (73.5%)
Diabetes mellitus
No 36 (73.5%)
Adult, dietary 5 (10.2%)
Adult, insulin dependent 8 (16.3%)
Juvenile diabetes 0 (0%)
Hypertension
No 11 (22.4%)
Treated with one drug 11 (22.4%)
Treated with two drugs 10 (20.4%)
Treated with three drugs 17 (34.7%)
Renal failure
No 47 (95.9%)
Creatinine 1.5-3.0 mmol/L; GFR 30-50 mL/min 1 (2%)
Creatinine 3.0-6.0 mmol/L; GFR 15-30 mL/min 1 (2%)
Creatinine >6.0 mmol/L; GFR <15 mL/min,
renal transplant
0 (0%)
Pulmonary disease
Asymptomatic 42 (85.7%)
Mild dyspnea 5 (10.2%)
Moderate dyspnea 2 (4.1%)
O2 needed, pulmonary hypertension 0 (0%)
Cardiac status
Asymptomatic 31 (63.3%)
Nonrecent MI (>6 months) or asymptomatic MI
on ECG
11 (22.4%)
Stable AP, arrhythmias, treatable heart failure 7 (14.3%)
Instable AP, recent MI (<6 months) 0 (0%)
Carotid status
No disease 43 (87.8%)
Asymptomatic, signs of disease 2 (4.1%)
TIA/CVA without rest symptoms 3 (6.1%)
CVA with rest symptoms 1 (2%)
Preoperative medication
Acenocoumarol 4 (8.2%)
Acetylsalicylic acid 38 (77.6%)
Phenprocoumon 0 (0%)
Clopidogrel 1 (2%)
Dipyridamole 4 (8.2%)
Statin 37 (75.5%)
American Society of Anesthesiologists class
I 2 (4.1%)
II 32 (65.3%)
III 15 (30.6%)
AP, Angina pectoris; CVA, cerebrovascular accident; GFR, glomerular
ﬁltration rate; MI, myocardial infarction; TIA, transient ischemic attack.
Table II. Clinical outcome of patients presenting with
an occluded endograft before endograft placement vs
postfailure
Before endograft
placement (N ¼ 49)
Postfailure
(N ¼ 49)
P
value
Ankle-brachial index,
mean (SD)
N ¼ 47
0.66 (0.19)
N ¼ 18
0.48 (0.16) .002
Rutherford classiﬁcation N ¼ 49 N ¼ 49
1 0 3 (6.1%)
2 0 14 (28.6%)
3 38 (77.6%) 18 (36.7%)
4 9 (18.4%) 7 (14.3%)
5 1 (2%) 4 (8.2%)
6 1 (2%) 3 (6.1%) .328
Level patent popliteal
artery
N ¼ 47 N ¼ 45
P1 37 (75.5%) 26 (53.1%)
P2 9 (18.4%) 8 (16.3%)
P3 1 (2%) 2 (4.1%)
Occlusion 0 9 (18.4%) .001
Anterior tibial artery N ¼ 48 N ¼ 42
Open 31 (63.3%) 22 (44.9%) .13
Open with stenosis 7 (14.3%) 6 (12.2%)
Occluded 10 (20.4%) 14 (28.6%)
Posterior tibial artery N ¼ 48 N ¼ 42
Open 37 (75.5%) 27 (55.1%)
Open with stenosis 5 (10.2%) 4 (8.2%) .03
Occluded 6 (12.2%) 11 (22.4%)
Peroneal artery N ¼ 47 N ¼ 42
Open 34 (69.4%) 30 (61.2%)
Open with stenosis 5 (10.2%) 3 (6.1%) .57
Occluded 8 (16.3%) 9 (18.4%)
SD, Standard deviation.
Values are given as number (%) unless otherwise indicated.
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ectomy of the common femoral artery was performed in
three patients (6.1%), of the external iliac artery in two
(4.1%), of the proximal SFA in one (2.0%), and of the
deep femoral artery in one (2.0%). Angioplasty of the popli-
teal artery was performed in four patients (8.2%). Twenty-
ﬁve patients (51%) were treated with only one endograft,
15 (30.6%) with two endografts, six (12.3%) with three
endografts, and three (6.1%) with four endografts. In thevast majority (93.9%) a 6-mm endograft was used. One
patient was treated with a 5-mm endograft, and the
remaining two patients were treated with a 7-mm endog-
raft. Thirty-seven patients (75.5%) were treated with
a regular endograft, and the remaining 12 patients
(24.5%) were treated with a heparin-bonded endograft.
After the procedure, 30 patients (61.2%) were treated
with dual antiplatelet therapy, eight (16.3%) received ace-
tylsalicylic acid 80 mg, and one (2%) was treated with clo-
pidogrel 75 mg only. Six patients (12.2%) were treated
with coumarin derivates because of other indications; two
of these patients also received acetylsalicylic acid (80 mg).
Of the remaining four patients (8.2%), data on postopera-
tive medication could not be retrieved. Seventy-four
percent of patients (n ¼ 36) were treated with statins. After
the initial procedure, clinical improvement was observed in
all but one patient. This patient had an early occlusion and
was treated with chemical thrombolysis. The ABI was
signiﬁcantly increased to 0.95 6 0.26; P < .001). The
30-day morbidity was 8.2% (n ¼ 4) and included wound
infection (n ¼ 1), hematoma (n ¼ 1), decubitus (n ¼ 1),
and a deep vein thrombosis (n ¼ 1). During the ﬁrst year
after the initial procedure, 15 of 49 patients (30.6%) who
ﬁnally failed already had an occlusion of the endograft
that was successfully treated by surgical thrombectomy
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underwent an additional angioplasty of the SFA or popli-
teal artery with (n ¼ 4) or without (n ¼ 7) additional stent
placement, and two patients underwent a toe amputation.
Outcome of failures. Median time from initial surgery
to failure was 7.3 months (range, 0.4-74.4 months). Six
endografts failed within the ﬁrst 30 days, 23 within the ﬁrst
6 months, and seven within the ﬁrst year after treatment.
The remaining endografts failed at 18 months (n ¼ 4), 28
months (n ¼ 4), 32 months (n ¼ 2), 43 months (n ¼ 2),
and 74 months (n ¼ 1). The Rutherford categories of these
patients after failure are listed in Table II. The overall clinical
state after endograft failure did not signiﬁcantly differ from
the clinical state before the initial procedure (3.16 1.3 vs 3.3
6 0.6, respectively; P¼ .33). Of the 49 patients, 21 (42.9%)
presented within the same Rutherford category, 18 (36.7%)
with an improved category, and 10 (20.4%) with a deterio-
rated category. Maximum walking distance after failure was
recorded in 22 patients (44.9%). Nineteen patients (38.8%)
had ameanmaximumwalking distance of 1586127meters,
which was not signiﬁcantly different from their maximum
walking distance before the initial procedure (P ¼ .69).
Three other patients (6.1%) had an unlimited walking
distance. Univariate analysis of cardiovascular risk factors did
not demonstrate any signiﬁcant correlationwith clinical state
after failure. Mean ABI after failure was signiﬁcantly lower
than the ABI before the initial procedure (P < .01).
However, the postfailure ABI was often missing. When
comparing the index ABI with the postfailure ABI in the 18
patients with a known postfailure ABI, the difference was
still signiﬁcant (0.646 1.4 vs 0.486 0.16, respectively; P<
.01). At the time of failure, the level at which the popliteal
artery was patent was located signiﬁcantly more distally
compared to that before baseline (P < .001).
Twelve patients (24.5%) with a failed endograft were
treated conservatively, and 37 patients (75.5%) underwent
a secondary reconstruction . Median follow-up of the
conservatively treated group was 9.9 months (range, 0.4-
36.4 months). Maximum walking distance in this subgroup
varied from 1000 meters to an unrestricted walking
distance. All patients in the conservative group were dis-
charged from further follow-up and were categorized as
Rutherford category 1.
Median follow-up after secondary surgery was 7.5
months (range, 0.7-100.2 months). In 34 patients
(69.4%), a secondary bypass was constructed. In 22 of these
patients (44.9%), an AK femoropopliteal bypass was con-
structed with either vein (n ¼ 9 ) or prosthetic material
(n ¼ 13). Twelve patients (24.5%) were treated with
a below-knee (BK) bypass with either vein (n ¼ 9) or pros-
thetic material (n ¼ 3). At 1 year, the primary patency was
55.1%, the primary-assisted patency was 62.3%, and the
secondary patency was 77.7% (Fig). Reinterventions of the
secondary bypass were performed in eight patients (36.4%)
with an AK bypass and in ﬁve patients (41.7%) with a BK
bypass, including angioplasty (n¼5), chemical thrombolysis
(n ¼ 1), and surgical thrombectomy (n ¼ 2). In three
patients a third bypass was constructed, all BK. In total, 2of 49 patients (4.1%) underwent a BK amputation, one after
unsuccessful chemical thrombolysis due to endograft failure
and one after failure of the secondary procedure. The patient
with an unsuccessful chemical thrombolysis had an infected
hematoma in the lower leg, possibly due to thrombolytic
treatment, and underwent a BK amputation 7 days after
bypass surgery. The other patient had a wound infection of
the foot after receiving an AK prosthetic bypass and under-
went a BK amputation 3 months after secondary surgery.
Both patients were diabetic and initially presented with
Rutherford category 3 and returned with category 3 and 6,
respectively, at the time of endograft failure. Amputations
were performed 0.2 and 39 months after failure of the
endograft, respectively.
DISCUSSION
The major drawback of using endografts for occlusive
arterial disease is potential occlusion of collateral arteries,
which may worsen clinical outcome in case of failure. In
the present study we found that failure of endografts
inserted for occlusive disease of the SFA does not deterio-
rate the clinical state of patients compared with the baseline
situation. Therefore, the data do not support the hypoth-
esis that endograft placement, possibly covering collateral
circulation, worsens patient clinical outcome after failure.
Seventy-six percent of patients with a failure needed
secondary surgery. The theory that use of covered stents
does not affect the options for secondary reconstructions
in case of failure could not be conﬁrmed, as 25% of patients
with a failure underwent a BK bypass.
Data from the present study may contribute to the
discussion on the role of endografts in the treatment algo-
rithm of SFA occlusive disease. It has been thought that
endografts may postpone surgery in this category of often
frail patients and may be a “bridge to surgery.” In the
present study we found that after mean follow-up of 2 years,
no secondary surgery was indicated in 89% of patients
because of patency of the bypass or no indication after
failure. Almost 25% of our population had no remaining
symptoms after occlusion of the endograft. The observa-
tion that 80% of patients did not show deteriorated clinical
outcome after failure and even may have improved suggests
that the covering of collaterals may not be clinically rele-
vant in this group of patients. However, this ﬁnding may
not be extrapolated to the popliteal artery, which is regu-
larly involved in TASC-II D lesions. It seems reasonable
to assume that preservation of collaterals in this area may
contribute to clinical outcome after failure. The use of
reentry devices or the combined anterograde-retrograde
approach may contribute to sparing as many collaterals as
possible at the popliteal level.7
Surprisingly, although endograft thrombosis was
related to a decreased ABI, the clinical state was often
similar or even improved compared with the baseline situ-
ation. The reason for this ﬁnding is unknown but may be
hypothesized to be the result of a phenomenon similar to
that occurring during walking-exercise training, where
increased clinical performance is not related to increased
Fig. Kaplan-Meier curve showing primary, primary-assisted, and secondary patency after secondary surgery.
SE, Standard error.
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state and ABI that might occur due to unknown reasons.
It is possible that treatment of the occlusion with an
endograft allowed the patient a rapid return to daily activ-
ities and provided the patient with sufﬁcient time to
develop new collaterals.
In the present study, 33% of patients showed a progres-
sion of disease in the popliteal artery distal from the bypass
after failure. This ﬁnding was reﬂected by a decreased ABI;
however, the quality and quantity of crural outﬂow vessels
were not affected, except for the posterior tibial artery. The
increased incidence of an occluded posterior tibial and
popliteal artery may be considered as an ongoing disease.
Obviously, this may have contributed to the occurrence
of failure. Due to this progression, a BK bypass was indi-
cated in one of three patients, possibly affecting the
outcome of the secondary procedure. Prosthetic material
was used in half of these patients, mostly because the
saphenous vein was unsuitable. This is in line with the
observation that only 45% of patients have a suitable
saphenous vein available reported by Gisbertz et al9 in
a randomized trial comparing surgery to remote endarterec-
tomy. The outcome of secondary surgery was rather disap-
pointing in the present study. Although the group was a mix
of AK and BK bypasses, primary 1-year patency was as low
as 55.1%. Nolan et al10 recently came to the sameconclusion in a retrospective analysis of 1880 lower-limb
bypasses. They found that prior ipsilateral endovascular
revascularization or bypass surgery, but also dialysis depen-
dence, use of a prosthetic conduit, and distal bypass target,
were independent predictors of higher 1-year amputation
and graft occlusion rates. The high failure rate of secondary
procedures might be due to progression of disease, the
vulnerability of this speciﬁc patient group, or other risk
factors such as comorbidity, poor runoff, and type of graft
material. In this study cohort, no composite or arm vein
conduits were used. The sample size of our cohort does
not allow further analysis and conclusions on this point.
Although secondary surgery is related to a relatively
high failure rate, the amputation rate was low in our study.
The amputation rate was 4% in the group of patients with
a failed bypass, but only after failure of a secondary proce-
dure. The amputation rate after failure of the secondary
procedure was only 6%, which is much lower than the
31% reported by Nolan et al.10 Our data are in line with
previous reports on the outcome of endografts for occlu-
sive SFA disease, which also described low overall amputa-
tion rates (range, 0%-4%).5,11,12 Deﬁning the role of
endografts for treatment of occlusive SFA disease remains
a challenge because it depends on many variables, including
the outcome of failures described here. In addition to
patency rates, issues such as quality of life and cost-beneﬁt
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randomized trials such as the Surgical versus Percutaneous
Bypass (SUPERB) trial will provide answers to settle this
debate.13
Limitations of the present study are mainly related to
the retrospective analysis of the prospective database.
Data were not always complete, which may have affected
outcome. Moreover, although this is the largest group of
failed endografts described to date, the sample size was still
relatively small. This renders a subanalysis of various factors
affecting the outcome of failure unreliable. Additional
comparative studies are indicated to conﬁrm our data.
During the study period, the design of the endograft was
changed because heparin-bonding technology and the
contoured edge were introduced. The present study design
does not allow a comparison between both endografts
because sample sizes were too low.
CONCLUSIONS
Failure of endografts is not related to deterioration of
the clinical state in the majority of patients, thereby
rejecting the hypothesis that coverage of collateral arteries
reduces the limb salvage rate after surgery. Secondary
procedures are related to low patency rates, but amputation
rates are low.
The assistance of Elisabeth A. Roovers with statistical
analysis of the data is greatly appreciated.
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